Breaking News

Cellenkos Completes FDA Registration of GMP Mfg. Facility

Makes cord blood-derived regulatory T-cell therapeutics at Houston site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellenkos, a clinical-stage biotechnology company focused on developing universal donor cell therapeutics derived from cord blood (CB) for the treatment of autoimmune diseases and inflammatory conditions, has completed the registration of its stand-alone, manufacturing facility as Good Manufacturing Practice (GMP) compliant with U.S. FDA. Cellenkos’ manufacturing facility makes cord blood-derived Regulatory T cell (Treg) therapeutics. Located in Houston, TX the facility covers 2,000 squ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters